Sweet C S, Rucinska E J
Merck Research Laboratories, Clinical Cardiovascular Research, West Point, PA 19486.
Eur Heart J. 1994 Dec;15 Suppl D:139-44. doi: 10.1093/eurheartj/15.suppl_d.139.
Losartan potassium (Cozaar) is an angiotensin II receptor antagonist (AT1 selective) which has undergone extensive clinical trials for the treatment of hypertension. This literature survey will review some of the pre-clinical findings with losartan in models of heart failure, and where appropriate, we will compare the haemodynamic findings in animals with similar studies completed in patients. The major conclusion from these trials is that losartan has clear haemodynamic benefits in patients in heart failure and that the drug appears to be well tolerated, with a low incidence of adverse experiences related to impaired renal function.
氯沙坦钾(科素亚)是一种血管紧张素II受体拮抗剂(AT1选择性),已针对高血压治疗进行了广泛的临床试验。本文献综述将回顾氯沙坦在心力衰竭模型中的一些临床前研究结果,并在适当情况下,将动物的血流动力学研究结果与在患者中完成的类似研究进行比较。这些试验的主要结论是,氯沙坦对心力衰竭患者有明显的血流动力学益处,且该药物似乎耐受性良好,与肾功能受损相关的不良事件发生率较低。